<DOC>
	<DOC>NCT00850499</DOC>
	<brief_summary>This is a randomized, open-label, active-control, multicenter Phase 2 study of VELCADE+fludarabine in comparison with rituximab+fludarabine in subjects with relapsed advanced follicular lymphoma. Eligible subjects will be randomized in a 1:1 ratio between the 2 treatment arms (55 subjects per arm).</brief_summary>
	<brief_title>Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Male or female subjects 18 years or older Histologically proven diagnosis of follicular nonHodgkin's lymphoma grades 1or 2 according to the World Health Organization classification Subjects must have received at least 12 doses (375mg/m2 or appropriately adjusted dose) of rituximab for the treatment of this lymphoma as single agent rituximab or in rituximabcontaining regimens as documented in the subject's medical record Documented relapse or progression following last antineoplastic treatment At least 1 measurable tumor mass (≥1.5 cm x ≥1.0 cm) Subjects with histological or clinical transformation to an aggressive lymphoma prior treatment with VELCADE or fludarabine. antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization nitrosoureas within 6 weeks before randomization radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization major surgery within 3 weeks before randomization chronic use of corticosteroids, such as dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>